Glyscend Therapeutics Completes $20.5M Financing Round to Advance Novel Oral Polymer Therapy for Type 2 Diabetes

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3hjQcOi
via IFTTT